SBRT and lenalidomide for solitary plasmacytoma
Treatments studied
Part of Cancer clinical trials.
This trial tests combining a focused, high-dose radiation treatment (SBRT) with the drug lenalidomide for people with a single plasma cell tumor (solitary plasmacytoma). The goal is to see if this combination works better than radiation alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a newly diagnosed solitary plasmacytoma (a single tumor made of plasma cells) that has been confirmed by biopsy.
- You must be between 18 and 80 years old.
- Your tumor must be a single spot on imaging (PET-CT or MRI) with no signs of multiple myeloma (no more than 10% plasma cells in bone marrow and no other organ damage).
- You must be able to lie still for the radiation treatment, and your doctor must think SBRT is safe for you.
- You must not have other cancers, uncontrolled infections, or certain heart, lung, or nerve conditions.
- You must not be pregnant, breastfeeding, or have a history of blood clots, autoimmune disease, or HIV, active hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study compares giving chemotherapy with radiation versus radiation alone for people with a single plasmacytoma (a localized plasma-cell tumor). It aims to see whether adding chemotherapy improves control of the disease while keeping side effects acceptable.
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
This trial tests a new combination of drugs (teniposide, a PD-1 checkpoint inhibitor, and selinexor) for people with relapsed or refractory primary central nervous system lymphoma. It aims to see if this three-drug approach can shrink tumors or slow the disease when previous treatments haven't worked.
This trial tests a new combination of radiation therapy and a bispecific antibody (a drug that helps your immune system attack cancer cells) for people with a single bone plasmacytoma that has only a small number of abnormal cells in the bone marrow. It aims to see if this approach can control the disease better than radiation alone.
This trial tests a new combination of drugs (CM336, isatuximab, bortezomib, and lenalidomide) for people newly diagnosed with primary plasma cell leukemia, a rare and aggressive blood cancer. It aims to see if this combination can help control the disease better.
This trial tests a combination of three drugs (poseltinib, rituximab, and lenalidomide) for people with primary central nervous system lymphoma that has come back or not responded to earlier treatment. The goal is to see if this new mix can help control the disease.
Hear when a new Solitary Plasmacytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.